Communicating Personal Genomic Information to Non-experts: A New Frontier for Human-Computer Interaction

4 authors, including:

Orit Shaer
Wellesley College
71 PUBLICATIONS 1,227 CITATIONS
SEE PROFILE

Oded Nov
New York University
92 PUBLICATIONS 1,814 CITATIONS
SEE PROFILE

Lauren Westendorf
Wellesley College
8 PUBLICATIONS 12 CITATIONS
SEE PROFILE

Some of the authors of this publication are also working on these related projects:

- HCI for Personal Genomics View project
- HoloMuse View project

All content following this page was uploaded by Orit Shaer on 15 May 2017.
The user has requested enhancement of the downloaded file. All in-text references underlined in blue are added to the original document and are linked to publications on ResearchGate, letting you access and read them immediately.
Communicating Personal Genomic Information
to Non-experts: A New Frontier for Human-Computer Interaction

Orit Shaer  
Wellesley College, Wellesley, MA, USA
oshaer@wellesley.edu

Oded Nov  
New York University, USA
onov@nyu.edu

Lauren Westendorf  
Wellesley College, Wellesley, MA, USA
lwestend@wellesley.edu

Madeleine Ball  
Open Humans Foundation, Boston, MA, USA
madeleine@personalgenomes.org
# Contents

1 Introduction 2

2 Personal Genetics Tutorial 6
   2.1 DNA sequencing .......................... 9

3 Background 13
   3.1 Historical context and new technologies ........ 13
   3.2 Online interaction with personal genomics .......... 14
   3.3 Omic technology ............................ 15
   3.4 Genomic data privacy and access .................. 17
   3.5 Public genomes and follow-up research ............ 19
   3.6 Characteristics of personal genomic data .......... 20
   3.7 Uncertainty in personal genomics ................. 20

4 Related Work 22
   4.1 Personal informatics .......................... 22
   4.2 Communicating uncertainty ....................... 23
   4.3 Interaction with biological data sets .............. 25
   4.4 DIY genome analysis ........................... 25

5 Emerging Framework for HCI for Personal Genomics 28
   5.1 Understanding users ............................ 29
5.2 Informing users ................................. 34
5.3 Empowering users .............................. 41

6 Broader Implications ........................... 48
   6.1 For HCI researchers .......................... 48
   6.2 For practitioners ............................. 49
   6.3 For society and policymakers .............. 49

Acknowledgements .............................. 51

References .................................... 52
Abstract

Recent advances in genetic testing and Internet technologies have led to a dramatic increase in the access non-experts have to their own personal genomic data. Such data are complex and sensitive, involve multiple dimensions of uncertainty, and can have substantial implications on individuals' behavior, choices, and well-being. Personal genomic data are also unique because unlike other personal data, which might change frequently, genomic data are largely stable during a person's lifetime; it is their interpretation and implications that change over time as new medical research exposes relationships between genes and health.

Future progress in genetic research and technologies is likely to further increase the availability of interactive personal genomic information to non-experts. This trend raises technological, ethical, and regulatory concerns related to how people make sense of, engage with, and rely on their personal genomic data. Such concerns are not only of paramount importance for health professionals and policymakers, but are also a pressing issue for human–computer interaction (HCI) research. HCI tools, methods, and practices can help make genomic information more accessible and understandable to non-experts. We argue that the complexity, importance, and personal relevance of this type of information makes understanding, informing, and empowering non-experts' interaction with personal genomics a key challenge that lies ahead for the HCI community.

In this article, we explore the roles HCI can play in helping non-experts contribute, understand, engage with, and share their personal genomic information. This article is also a call-to-action for those of us interested in the intersection of personal informatics and HCI, and, more broadly, in facilitating non-expert interaction with large amounts of complex, personal, and uncertain information.

DOI: 10.1561/1100000067.
1

Introduction

“A firsthand familiarity with the code of life is bound to confront us with the emotional, moral and political baggage associated with the idea of our essential nature. People have long been familiar with tests for heritable diseases, and the use of genetics to trace ancestry — the new “Roots” — is becoming familiar as well. But we are only beginning to recognize that our genome also contains information about our temperaments and abilities. Affordable genotyping may offer new kinds of answers to the question “Who am I?” — to ruminations about our ancestry, our vulnerabilities, our character and our choices in life.” [Pinker, 2009]

Recent years have seen a dramatic growth in the availability of personal genomic data to non-experts, often online and in interactive forms [Dudley and Karczewski, 2013]. The field of personal genomics is rapidly growing, as the cost of sequencing a human genome has fallen from approximately $100 million in 2001 to $1,000 in 2016, a rate much faster than Moore’s Law [Church, 2005] (see Figure 1.1). The Precision Medicine initiative and similar health research projects increasingly highlight the potential for genetic data to become a
Figure 1.1: A graph demonstrating the precipitous decline in genome sequencing cost since the completion of the Human Genome Project in 2001. Whole genome sequencing is now around $1,000 per genome, five orders of magnitude lower than the $100 million cost of the Human Genome Project (from the National Human Genome Research Institute).

standard component of health records [NIH]. In the meantime, direct-to-consumer genetic testing (DTCGT) companies have made genomic information available to millions of individuals without the involvement of a healthcare provider through online platforms. These individuals are thereby confronted with unprecedented amount of potentially sensitive information about their genetic data, which influences their decisions, emotional states, and wellbeing [Davies, 2010].

The use of Web-based interactive technologies to deliver personal genomic information raises questions about how non-experts make sense of, engage with, and rely on their personal genomic data. Future progress in genetic research and technologies is likely to further increase the availability of interactive personal genomic information
Introduction
to non-expert users. This trend raises technological, ethical, and regulatory concerns. For example, in 2013, the U.S. Food and Drug Administration (FDA) ordered 23andMe, a direct-to-consumer genetic testing company, to stop providing risk assessment reports, stating that “serious concerns are raised if test results are not adequately understood” [Pollack, 2013]. Providing consumer reports partially resumed in 2015 when 23andMe received FDA approval for a vetted set of gene variant interpretations [Pollack, 2015]. While such concerns are imperative for policymakers, it is also vital to consider these issues from the perspective of human–computer interaction (HCI) research.

Specifically, the highly personal and dynamic nature of individually-relevant personal genomic information, which is constantly updated based on new research results, raises important HCI questions, including: what are the functional requirements for supporting meaningful engagement of non-experts’ with personal genomic information? How can we design effective interaction with personal genomic information? How can we evaluate the effectiveness of techniques for interaction with personal genomic information? Can user interface design interventions impact users’ willingness to share their personal genomic data?

An additional important aspect of communicating personal genomics to non-experts is the understanding of the vast commonalities and genealogical similarities among people from different racial and ethnic backgrounds. Future HCI work on personal genomics has a critical role in making these commonalities apparent to users, just as much as the differences.

Because the technology that enables non-experts to interact with personal genomic information is new, there is little HCI research on it. Given the tremendous growth in the scale and scope of personal genomic information available to non-experts, personal genomics represents a new and fast-growing frontier where HCI research can make a significant difference in people’s lives.

This article explores the roles HCI can play in helping non-experts to understand and engage with personal genomic information. It is also a call to action for those of us interested in the intersection of personal informatics and HCI, and, more broadly, the facilitation of interaction
of non-experts with large amounts of complex and uncertain personal information.

We begin with a brief tutorial of personal genetics (Section 2), followed by a description of the historical context and new technologies of personal genomics, and a discussion of the characteristics of personal genomic data (Section 3). We then survey related work from human–computer interaction and personal informatics (Section 4). Section 5 presents a framework for HCI research focusing on understanding, informing, and empowering non-expert users of personal genomics. Finally, in Section 6 we discuss broader implications for HCI researchers, for personal genomics practitioners, for policy makers, and for society.
The term personal genetics describes the information which an individual has inherited from their biological parents. An individual’s physical traits — features of their biology, body, and health — are partly inherited and often are influenced by environmental and behavioral factors. At its most fundamental level, this inheritance is discrete in nature: units of inheritance are called genes. Some traits, like rare diseases and ABO blood types, are associated with a single gene. Many other traits (e.g. risk for diabetes, or height) are the products of many genes, and are also influenced by environmental factors like diet.

The biological basis of inherited traits is DNA — deoxyribonucleic acid, a linear chain of nucleic acids found in all cells. The sequence of these four nucleic acids, a.k.a. bases — adenine, cytosine, guanine, and thymine (A, C, G, and T) – is molecular information that drives almost all features of life. DNA is inherited, copied, and passed from parent to child. The collective set of DNA molecules for an individual, inherited from their mother and father, is their genome. Each gene is a section of a DNA molecule that contains information for creating a specific type of protein, each of which affects a specific aspect of cell biology.
Proteins are the primary functioning units of life and play a variety of roles: they can be structural elements, or they may drive chemical reactions that would not otherwise occur.

Each individual human genome consists of two slightly different copies of 3 billion nucleic acids, organized into 23 pairs of chromosomes (Figure 2.1). As demonstrated in Figure 2.2, genes are distributed along chromosomes and are often interleaved with nonfunctional DNA. The functional fragments of gene DNA, accounting for 1% of the genome, are called exons (because this sequence is “exported” and used elsewhere in the cell).

Genetic variants account for inherited differences between individuals. However, because most of the genome is nonfunctional, most genetic variants have no biological effect. Those that do have an effect typically occur in exon regions: and they have a biological effect because they change the protein the gene produces.
Figure 2.2: Each chromosome consists of a single, densely packed DNA strand. Genes occur as segments within the DNA strand, and genetic data is encoded within the sequence of four possible bases at each position in the DNA chain: Adenine, Cytosine, Guanine, and Thymine (A, C, G and T). Genes are often interleaved with nonfunctional DNA (intron regions). Genetic variants which change a gene’s behavior typically affect exon regions — the DNA sequences used to produce a gene’s protein product.

Each genome exists largely in duplicate: for most genes and DNA segments, one copy is inherited from each biological parent. When an individual carries a genetic variant, it could be present in both genes (homozygous, referring to the sameness of each copy) or it could be present in only one (heterozygous). The exception to this is the sex chromosomes: males have only one copy of each “X” and “Y” chromosome, and their variants on these chromosomes are called hemizygous.

The biological consequences of which involve genetic variants in a single gene can be affected by whether both copies of a gene carry
2.1 DNA sequencing

There are various technologies for “reading” DNA molecules. Since information is contained within the molecular sequence of the DNA’s nucleic acids (i.e., bases), these technologies are commonly referred to as DNA sequencing. Human genome sequences are mostly identical to each other: sequence differences between two individuals account for just 0.1% of all nucleic acids. These few genetic variants account for many differences between two humans.

Although sequencing the human genome cost $3.6 billion when it was completed in 2003 [NHGRI, 2016], improvements to DNA sequencing have since outpaced Moore’s Law: whole genome sequences can now be purchased for under $1000 (Figure 1.1) [Keshavan, 2016, Regalado, 2016]. Two major technologies have led to vastly increased efficiency in producing genetic data: high-throughput DNA sequencing, and microarray-based genotyping. The first technology, high-throughput DNA sequencing, is comprehensive — it enables whole genome sequencing (see Figure 2.4) and exome sequencing (a lower-cost option that targets gene exon regions for around $500 [Molteni, 2016]). The second technology, microarray-based genotyping, is less comprehensive but provides a lower-cost option: for $100–$200 it can be used to test a million specific locations that are known to vary between individuals [23andMe, AncestryDNA]. Because genotyping is the lowest cost

the same variant. Genetic variants that only have an effect when both copies of a gene are affected are called “recessive” (these typically have little to no effect when heterozygous, resulting in an individual having carrier status). While recessive variants have no immediate impact on individual health, carrier status for genetic diseases can influence reproductive decisions. In contrast, genetic variants that always have an effect are called dominant. Not all variants are clearly recessive or dominant: for example, a variant may have a weak effect when heterozygous, and a stronger effect when homozygous. Figure 2.3 explains the effect of genetic variants within a single gene, also referred to as monogenic effects.
Monogenic Effects

Recessive
A single copy has an effect. Sometimes a spontaneous mutation. Examples: achondroplasia, hypertrophic cardiomyopathy, Huntington's disease
- Homozygous affected
- Heterozygous unaffected carrier
- Compound
  - Homozygous affected - two different broken variants

Dominant
Typically a "broken" gene. No effect as long as one functioning copy remains. Examples: cystic fibrosis, blue eyes, albinism, stomach flu resistance
- Heterozygous affected
- Homozygous affected, though very rare or never seen

Additive
One copy has some effect, two copies have a stronger effect. Magnitude of effect depends on the variant. Example: Alzheimer's risk (APOE4)
- Heterozygous affected, small/moderate effect
- Homozygous affected, strong effect

X-Linked
In genetic males (XY) a single copy has an effect, but acts as a "recessive" in genetic females (XX). Examples: colorblindness, hemophilia
- Hemizygous affected

Figure 2.3: Monogenic effects involve variants in a single gene. Whether variants in a gene have an effect on traits or health depends on how many copies of the gene have variants, and on the variant’s inheritance pattern: Dominant, Recessive, X-linked, or Additive.

option, it is currently used by leading direct-to-consumer genetic testing companies like AncestryDNA and 23andMe.

Personal genetic information gained through the process of genotyping or high-throughput DNA sequencing can be used for two seemingly disparate purposes: ancestry and biological traits. Ancestry information
2.1. DNA sequencing

Figure 2.4: Current technology for high-throughput DNA sequencing starts with a biological sample (e.g. blood or tissue). A parallelized sequencing process generates millions of short “reads”. Reads are then computationally assembled to determine an individual’s whole genome sequence [from the National Human Genome Research Institute].

can be discovered because DNA is inherited: similarities between individual genomes can be used to discover near relatives (e.g. cousins), as well as predict more distant ancestry (i.e. geographical origins and associations with race/ethnicity). But because DNA is responsible for biological function, it can also be interpreted to understand biological
traits. This health-relevant aspect of genome information has been subject to regulatory concerns (e.g. by the United States Food and Drug Administration), because it can be used to determine clinically relevant information. As a result, while some products have interpreted customers’ genetic data for both traits and ancestry purposes (e.g. 23andMe), others avoid regulatory issues by only analyzing ancestry aspects (e.g., AncestryDNA).
3

Background

3.1 Historical context and new technologies

Prior to the rapid expansions in genetic technologies, genetic testing was confined to a specialized aspect of clinical practice. Testing for the diagnosis of a suspected genetic disorder (like Huntington’s disease or cystic fibrosis) occurred only for affected individuals and their immediate family, in rare cases. The data and information produced was very specific, and was interpreted by a lab specialized in testing for the particular disease. The information was conveyed to the patient by trained experts called genetic counselors. These models for information management have been challenged by developments in genomic technology, which have enormously expanded both the scope of genetic data available and the number of individuals tested.

As outlined above, developments in genetic technologies have vastly lowered costs, creating a massive expansion in the scope of data produced by genetic testing. Analysis of this data is an area of ongoing development, as researchers and clinicians adapt and combine disease-specific and gene-specific analytical approaches. The ability to perform comprehensive analysis is also limited by current knowledge, as our understanding of the effects of gene variants continues to evolve.
Parallel to this expansion in the amount of data produced is an expansion in the **scope of individuals tested**. While genome and exome technologies have seen increasing clinical applications [Manolio et al., 2013], lowered costs for testing have also led to the growth of direct-to-consumer genetic testing (DTCGT) companies [Turrini and Prainsack, 2016]. These companies have brought genetic testing outside the clinic to millions of users (e.g. [23andMe, AncestryDNA]), selling online products that enable individuals to access their own genetic data online for the purposes of expanding their understanding of personal ancestry, health, and biology.

### 3.2 Online interaction with personal genomics

The expansion of both the amount of data and the scope of individuals involved in genetic testing has led to radical changes both in the nature of the information returned and in the process of returning data. Automated methods and online tools have become necessary features for sharing extensive information with many individuals. In addition, the scale of the underlying data defies comprehensive interpretation, and scientific understanding of the data is constantly evolving — many potentially meaningful genetic variants are not yet known to be meaningful. What can be understood from genetic data, the potential for re-interpretation, and how to share that knowledge have provoked extensive debates [Hughes, 2013, Conley, 2014].

DTCGT companies enable individuals to acquire genetic information without the involvement of a healthcare provider by sending a saliva sample to a DTCGT company, at a relatively low cost. To date, DTCGT do not offer whole genome or exome sequencing, but rather microarray-based genotyping. Results are delivered through online interactive reports. Several popular DTCGT services offer interactive online reports of ancestry information (e.g. 23andMe, AncestryDNA, and FamilyTreeDNA). The service 23andMe also provided risk assessment results for about 250 traits and conditions; however, in response to concerns from the FDA current 23andMe health-related reports return
3.3 Omic technology

The revolution in genetic data is paralleled by other omic technologies that bring similarly broad, untargeted biological data to clinical and direct-to-consumer contexts, including microbiome and metabolite profiling [Khamsi, 2014, Seetharaman, 2015, Dillet, 2015]. Microbiome profiling uses high-throughput DNA sequencing to profile microbiota that live in the human gut, as well as other tissues, potentially impacting digestion, weight, and other aspects of health. Metabolite profiling assays numerous small molecules in the blood, and can reveal abnormalities in metabolism and health. Like genome analyses, these and other omic technologies produce large amounts of data relevant to many potential conditions. It seems likely that these technologies will confront parallel challenges with management of comprehensive data, potentially limited and shifting interpretations, and the demand for tools to communicate information to non-expert individuals.
**INHERITED CONDITIONS**

These reports show your results for specific genetic variants that can cause certain health conditions. Many of these conditions are recessive, meaning that they only occur when you have two variants for that condition, one inherited from each parent. If you have inherited just one variant, you are said to be a "carrier". Carriers usually do not have the condition, but can pass the variant on to their children. Note that these reports cover only a subset of possible variants that may be linked to a condition. It is thus possible to have other variants not covered by these reports.

<table>
<thead>
<tr>
<th>NAME</th>
<th>CONFIDENCE</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARSACS</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Agenesis of the Corpus Callosum with Peripheral Neuropathy (ACCPN)</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Alpha-1 Antitrypsin Deficiency</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Autosomal Recessive Polycystic Kidney Disease</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>BRCA Cancer Mutations (Selected)</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Beta Thalassemia</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Bloom’s Syndrome</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Canavan Disease</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Congenital Disorder of Glycosylation Type 1a (PMM2-CDG)</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Connexin 26-Related Sensorineural Hearing Loss</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>D-Bifunctional Protein Deficiency</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
<tr>
<td>DPD Deficiency</td>
<td>5 Stars</td>
<td>Variant Absent</td>
</tr>
</tbody>
</table>

**Figure 3.1:** An example of the “Inherited Conditions” report produced by 23andMe, screening for serious genetic conditions. In this report, the user is presented information for every tested gene and location. Because these tests are usually negative (no disease-causing variant found), it is common for users to have over 50 results that are entirely “Variant absent”. Uncertainty in interpretation of variant effects is represented by a confidence score (number of stars in the “Confidence” column).
3.4. Genomic data privacy and access

Commercial companies typically provide their customers with access to raw genetic data. This raw data contains an individual’s gene variant information, without interpretation, and can potentially be reanalyzed using third-party tools and resources. In contrast, research studies only
rarely give their research subjects access to their raw genetic data, possibly due to legal concerns regarding regulation of genetic testing [Evans, 2014, Karow, 2014]. Privacy of genetic information has been a major concern for many individuals interested in genetic data analysis. Because it contains extensive ancestry and trait information, genetic data is potentially identifiable (especially when combined with additional data), and in 2013 a re-identification study demonstrated that inference of surnames from Y-chromosome data could be used to re-identify dozens of “anonymous” public research genomes [Gymrek et al., 2013]. Many individuals are concerned about discrimination in access to insurance based on genetic data despite some legal protections (e.g. the United Status Genetic Information Nondiscrimination Act of 2008) [EEOC, 2008; Sanderson et al., 2016]. Discrimination is still possible in other contexts such as employment and in some cases can be impossible to regulate. Genome data privacy has thus been a concern in both research
and commercial contexts [Nature, 2013, Phillips, 2015], and controlled-access sharing for genome data research is common (e.g. as performed by the United States Database of Genotypes and Phenotypes, dbGaP), while commercial groups often promise privacy for individual-level genetic data.

### 3.5 Public genomes and follow-up research

The Harvard Personal Genome Project (PGP) is a research study, initiated in 2005 by George Church of the Harvard Medical School, that seeks to improve understanding of how genomic and environmental factors influence human traits through the creation of a public dataset [Church, 2005]. PGP volunteers agree to share their genomic sequences, as well as health data, with the scientific community and the public. Today, more than 5,000 volunteers are enrolled in the project through a process of open consent [Lunshof et al., 2008, Ball et al., 2012, 2014] and have agreed to share their genomic information publicly. Of these, over 300 individuals have had whole genome sequencing data produced by the project and publicly shared.

Public genome data produced by the Harvard PGP is accompanied by a preliminary research report produced by the GET-Evidence system [Ball et al., 2012]. This report is given to participants prior to public data release, to better inform them regarding the data they are choosing to publicly share. Upon consent, these reports are publicly shared alongside public genome data, as is the underlying database for variant interpretations.

The Harvard PGP is distinguished from other public genome resources in its ongoing work with participants. The PGP has historically invited other research groups to work with its volunteers, enabling follow-up research with this population and providing a unique opportunity for studying HCI in genomic data. This process is now streamlined and explicitly supported within the Open Humans platform, a successor project to the PGP. In Open Humans, researchers can recruit and work with PGP participants, as well as other members with other
public and private genetic data such as microbiome, activity logs, GPS, and other diverse data sources [Open Humans].

3.6 Characteristics of personal genomic data

The data produced by genome sequencing, exome sequencing, and comprehensive genotyping spans all ∼20,000 genes of the human genome. Comparing any two genomes reveals millions of genetic differences, and the database of all observed variations in all humans currently exceeds 150 million genetic variants [dbSNP, 2016]. The information that can be learned from this comprehensive data is diverse, complex, and evolving.

One of the most popular uses of this information is for ancestry analysis. By comparing individual data with population-level information, analysis of DNA segments can predict racial and ethnic origins. More recent ancestry — the discovery of cousins and near relatives — is also possible through large databases that detect shared segments of DNA between individuals. In addition to ancestry, everything about ourselves that is heritable is — in theory — contained within the data. Although many gene variants have disease associations that imply clinical utility, individuals are also motivated by curiosity and entertainment to learn about variants with no medical purpose (e.g. physical traits) [Vayena et al., 2012]. Analyzing data to produce health and trait insights is daunting: ClinVar, a public database aggregating reported effects, now has over 100,000 gene variants. Aggregating and filtering results to facilitate understanding of any individual genome is challenging, and it is still unclear how to combine information from multiple genes affecting a single trait or disease.

3.7 Uncertainty in personal genomics

The relationships between genes and health effects are in many cases not well understood, and knowledge about such relationships evolves dynamically with the development of new technologies, processes, and research results. Individuals are therefore often required to continuously reconsider their genomic information against the most current research evidence. As a result, interaction with personal genomic data
is unique compared to other forms of personal data, where the dynamic element is often the data itself, which is usually sampled at intervals over time with the objective of creating an incremental feedback loop to influence an individual’s behavior [Li et al., 2011]. In such traditional forms of personal informatics, uncertainty often results from the context and accuracy of data tracking. Genomic data, on the other hand, are largely stable during a person’s lifetime — 99.9999% accuracy is typical, and continues to improve [Peters et al., 2012]. The uncertainty in personal genomics stems from the interpretation of the data, and from the evidence of related implications for the user’s health and traits (see, for example, 23andMe’s “confidence” score, Figure 3.1). This form of uncertainty arises because our understanding of genetic variants changes over time: hypotheses are corrected or updated, and new medical research exposes new relationships between people’s genetic makeup and their effects.
4

Related Work

4.1 Personal informatics

Quantified Self, also known as personal analytics [Regalado, 2013] and personal informatics [Li et al., 2010], refers to research and practice involving communities, practices, and systems that help people collect and reflect on their personal information. The increasing availability of low-cost sensors has accelerated the practice of self-tracking as well as the rise of the Quantified Self movement [Quantified Self]. Researchers and designers have developed and studied numerous self-tracking technologies and applications for health and wellness [Klasnja and Pratt, 2012, Swan, 2009]. An underlying assumption driving the growth of this field is that individual's knowledge of their data facilitates reflection, which in turn leads to self-discoveries and to lifestyle changes. While researchers of personal informatics and Quantified Self acknowledge the value of self-tracking technologies [e.g., Bentley et al., 2013, Consolvo et al., 2008, Lin et al., 2006, Mamykina et al., 2008, Patel et al., 2012], they also discovered several barriers toward the adoption and effective use of self-tracking technologies including data integration
4.2 Communicating uncertainty

One of the key tasks of a personal genomic report is to communicate to its reader the uncertainty that is associated with their data and its implications. An abundance of work has investigated the visualization of uncertain information in other domains.

Existing taxonomies for communicating uncertainty identify sources of uncertainty (and visual presentation techniques) [Skeels et al., 2008, Taylor and Kuyatt, 1994, Thomson et al., 2005]. Additional work
explores cognitive biases of decision-making under uncertainty and corrective visual approaches [Inbar, 2007, Tversky and Kahneman, 1974]. In particular, researchers explored public perception and communication of weather forecast uncertainty, showing that the general public understands that uncertainty is inherent in weather forecasts as well as some of the factors that increase uncertainty [Morss et al., 2008, Joslyn and Savelli, 2010, Joslyn et al., 2013]. The research shows that when communicated carefully, uncertainty in forecast leads to better outcomes such as increased precautionary action for extreme weather events [LeClerc and Joslyn, 2012, Savelli and Joslyn, 2012]. Research also indicates that communicating uncertainty in an interface or visualization of weather forecast could increase trust and help people make better decisions [Gigerenzer et al., 2005, Roulston et al., 2006, Joslyn and LeClerc, 2013]. Evidence from other application domains such as remaining driving range in electric cars [Jung et al., 2015] and weight scale [Kay et al., 2013] indicates that not including uncertainty information can decrease trust in the application.

Numerous applications tracking new types of personal and often uncertain data have explored how to present the data to encourage behavior change and reflection [Rooksby et al., 2014, Epstein et al., 2015, Choe et al., 2015, Lee et al., 2015]. A study comparing visualizations of uncertainty found that participants’ judgment of these visualizations was significantly influenced by familiarity, ease of understanding, and visual appeal [Greis et al., 2016]. Another study comparing the impact of various representations of uncertainty on different activities concluded that different types of visualizations lead to different learning outcomes and suggested that an interactive display may be best for communicating uncertain information [Nadav-Greenberg et al., 2008]. Similarly, a different study shows that the amount of presented uncertainty leads to different outcomes of risk taking within a game context [Greis et al., 2016].

This growing body of work is important for researchers to draw upon when studying how to communicate uncertainty of personal genomic information.
4.3 Interaction with biological data sets

To date, little HCI research has focused on direct user engagement with personal genomic information. Instead, researchers focused on developing new ways of interacting with large-scale and complex biological data sets for use as a platform to explore novel interaction techniques, such as tangible interaction [Shaer et al., 2013, Manshaei et al., 2016]. Systems developed include a tangible interface for scientists designing new DNA molecules [Schkolne et al., 2004], a tabletop tangible interface for system biologists [Wu et al., 2011], and several tabletop interfaces for interactive visualization of biological data sets in informal and formal learning settings, such as DeepTree [Block et al., 2012] and PhyloGenie [Schneider et al., 2012]. G-nome Surfer [Shaer et al., 2011] is a tabletop interface for collaborative exploration of genomes; Tangible mtDNA is an active tangible and tabletop system for collaborative exploration of mitochondrial DNA sequencing data in breast cancer patients [Manshaei et al., 2016]. However, these systems were not designed to support non-expert users in the self-exploration of their own genomic data but rather to support researchers and learners in exploring genomic data sets.

4.4 DIY genome analysis

Individuals can potentially explore and analyze their genetic data in a variety of ways including: exploring information provided by the primary testing service; secondary analyses performed by third parties; or personal analyses drawing on various resources and databases. However, information from primary testing services is often the only information explored. In some services this information can be quite extensive. 23andMe, for example, provides in-depth reports on each of the variants included in the health and trait analyses. These reports summarize current research, population statistics, and provide links to primary literature. Due to regulatory concerns, however, many other testing providers avoid providing information regarding health and traits associated with genetic variants. Even services that do provide this information (e.g. 23andMe) are still limited to the set of variants
Table 4.1: A selection from a growing variety of products giving consumers to access to genetic data, as well as analysis tools and resources for interpretation.

<table>
<thead>
<tr>
<th>Tools, products, &amp; resources</th>
<th>Type(s)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>23andMe</td>
<td>Genotyping testing service</td>
<td>Primary testing service</td>
</tr>
<tr>
<td></td>
<td>Ancestry interpretation</td>
<td>Exportable raw data</td>
</tr>
<tr>
<td></td>
<td>Relative finding</td>
<td>Over 1 million customers</td>
</tr>
<tr>
<td></td>
<td>Health &amp; trait interpretation</td>
<td></td>
</tr>
<tr>
<td>AncestryDNA</td>
<td>Genotyping testing service</td>
<td>Primary testing service</td>
</tr>
<tr>
<td></td>
<td>Ancestry interpretation</td>
<td>Exportable raw data</td>
</tr>
<tr>
<td></td>
<td>Relative finding</td>
<td>Over 2 million customers</td>
</tr>
<tr>
<td>ClinVar</td>
<td>Variant information database</td>
<td>Aggregated reports</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Expert resource</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Public domain</td>
</tr>
<tr>
<td>Enlis Genomics Personal</td>
<td>Variant function analysis</td>
<td>Accepts data import</td>
</tr>
<tr>
<td>Exome Aggregation Consortium (ExAC)</td>
<td>Variant information database</td>
<td>Variant frequency information</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Share-alike license</td>
</tr>
<tr>
<td>FamilyTreeDNA</td>
<td>Genotyping testing service</td>
<td>Primary testing service</td>
</tr>
<tr>
<td></td>
<td>Ancestry interpretation</td>
<td>Accepts data import</td>
</tr>
<tr>
<td></td>
<td>Relative finding</td>
<td>Exportable raw data</td>
</tr>
<tr>
<td>Gedmatch</td>
<td>Ancestry interpretation</td>
<td>Accepts data import</td>
</tr>
<tr>
<td></td>
<td>Relative finding</td>
<td></td>
</tr>
<tr>
<td>Genos</td>
<td>Exome sequencing</td>
<td>Primary testing service</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exportable raw data</td>
</tr>
<tr>
<td>Illumina Understand Your Genome</td>
<td>Whole genome sequencing</td>
<td>Primary testing service</td>
</tr>
<tr>
<td></td>
<td>Health &amp; trait interpretation</td>
<td>Exportable raw data</td>
</tr>
<tr>
<td>Interpretome</td>
<td>Ancestry interpretation</td>
<td>Data analysis software</td>
</tr>
<tr>
<td></td>
<td>Health &amp; trait interpretation</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
4.4. DIY genome analysis

Table 4.1: (Continued)

<table>
<thead>
<tr>
<th>Tools, products, &amp; resources</th>
<th>Type(s)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Online Mendelian Inheritance in Man (OMIM)</td>
<td>— Gene information database</td>
<td>— Curated summaries of primary literature</td>
</tr>
<tr>
<td></td>
<td>— Variant information database</td>
<td></td>
</tr>
<tr>
<td>PubMed</td>
<td>— Publications database</td>
<td>— Search primary literature</td>
</tr>
<tr>
<td>Promethease</td>
<td>— Health &amp; trait interpretation</td>
<td>— Accepts data import</td>
</tr>
<tr>
<td>SNPedia</td>
<td>— Variant information database</td>
<td>— Crowdsourced</td>
</tr>
<tr>
<td></td>
<td>— Non-commercial license</td>
<td></td>
</tr>
<tr>
<td>Veritas Genetics</td>
<td>— Whole genome sequencing</td>
<td>— Primary testing service</td>
</tr>
<tr>
<td></td>
<td>— Health &amp; trait interpretation</td>
<td>— Exportable raw data (added fee)</td>
</tr>
</tbody>
</table>

they are reporting upon. Thus, many individuals are interested in additional analyses of raw genetic data from primary providers.

There are a variety of third-party services and tools for analyzing genetic data, which provide tools for ancestry analysis or health/trait analysis (see Table 4.1). Services like FamilyTreeDNA and Gedmatch accept third-party data for ancestry analysis, and enable relative finding within their communities. Health and ancestry analyses are also possible using third-party tools like Enlis, Interpretome, and Promethease. These tools often provide links to resources and databases containing variant function predictions and reported effects (e.g. ClinVar, ExAC, OMIM, SNPedia, PubMed).

Table 4.1 presents a selection of primary testing providers, as well as third-party analysis services, tools, resources, and databases used for exploring personal genomic information. For each of these we summarize its main features.

The rest of this article lays the ground for future HCI research on direct engagement of non-experts with personal genomics.
In this section, we present a framework for HCI research for personal genomics. The framework provides a research agenda, which investigates the role of HCI methodology and interventions in personal genomics. We center our framework on three themes — Understanding, Informing, and Empowering users:

*Understanding users* — examining users’ motivations, needs, information practices, and concerns in engaging with and sharing their personal genomic information;

*Informing users* — investigating how variations in user interface design affect users’ deliberation on their consent to genetic testing, their comprehension of genomic information, as well as their intentions to share such information with others;

*Empowering users* — focusing on the design and development of interactive tools that empower users to engage with their personal genomic information over time in applicable and meaningful ways.

For each theme we review the recent and current research, and highlight open questions for future HCI research.
5.1 Understanding users

Since the technology that enables lay people to interact with personal genomic information directly is relatively new, many questions remain open regarding non-expert engagement with personal genomic information.

For example, what motivates non-expert individuals to acquire personal genomic information? What concerns do they have about engaging with personal genomics? What are their goals in exploring their personal genomics? How do they learn from their personal genomic information? Which tools do they use and how do users document and organize their findings? How do they validate their findings? What kind of information do they share and with whom?

Gaining insights into individuals’ motivations, needs, information practices, and concerns of engaging with and sharing their personal genomic information plays a vital role in the design of new interactive tools that empower non-experts to learn from their personal genomic information. However, the importance of understanding personal genomic users goes beyond the development of new tools to informing future policy about personal genomics as well as to envisioning the future of personal informatics.

5.1.1 Current research on understanding users

Several studies have investigated the motivation of DTCGT users. In these studies, curiosity was mentioned as the participants’ primary motivation for undergoing genomic testing [Goldsmith et al., 2012]. Most participants wanted to learn more about themselves, were curious about their genetic makeup, or wanted to learn about individual genetic risk factors. Participants also stated that they would use information gained from the test to take personal responsibility for their future health [McGowan et al., 2010]. Other themes included fascination with genealogy, contribution to research, and recreation [Goldsmith et al., 2012]. Studies also identified several concerns among DTCGT users, including privacy, as well as the nature of the results and their future impact [Kuznetsov et al., 2015]. For example, users may develop anxiety
surrounding the risk of particular conditions, the possibility of discrimination from employers and insurance companies, or the possession of sensitive and personal data. The Impact of Personal Genomics Study [PGen, 2016] is a current large-scale longitudinal study that surveys consumers of two U.S. DTCGT providers — 23andMe and Pathway Genomics — to determine the characteristics of consumers, the psychological, behavioral, and health impact of genetic testing, and the ethical, legal, and social issues associated with DTCGT services.

Little empirical data exists about the attitudes and motivations of people who have had their whole genome sequenced [Goldsmith et al., 2012, Linderman et al., 2016], since a relatively a small number of users around the world have had their entire genome sequenced and returned to them. Of the individuals that have access to their whole genome information, a significant subset have been volunteers of the Harvard Personal Genome Project (PGP). We established a design partnership with the Harvard PGP and have collaborated closely with its researchers and volunteers to study the information practices and needs of personal genomics users. PGP volunteers can be categorized as early adopters [Rogers, 2003] or extreme user group [Choe et al., 2014, Troshynski et al., 2008]. They tend to have advanced education and possess favorable attitudes toward science. Their motivations and information practices might not be generalizable or applicable to the broader population. However, in areas that evolve rapidly based on technical and scientific innovations, the perspectives of early adopters provide important insights, because they have used the existing technologies and have had the opportunity to identify challenges and potential solutions [Choe et al., 2014, Troshynski et al., 2008].

To better understand the needs and information practices of PGP participants, we conducted a qualitative study with 63 participants from the Harvard PGP volunteer community [Shaer and Nov, 2014]. Participants filled out an online questionnaire that consists of 10 open questions (see Shaer and Nov [2014]) regarding their motivation, goals, and information practices, in addition to demographics questions. Although study participants were motivated by a diverse set of goals, ranging from understanding traits, to identifying health risks,
5.1. Understanding users

**Figure 5.1:** Five common information tasks of non-expert personal genomic users.

From an HCI perspective, these findings can serve as a basis toward the design of new interaction techniques and tools for personal genomics. To that end, it is important to gain further and more nuanced insight into how users engage with, and learn from, their annotated personal genomic reports. For that reason, we conducted a second qualitative study of personal genomics users [Shaer et al., 2015]. We interviewed and observed 36 PGP participants, who have had their whole genome sequenced, as they explored their personal genomic data using the GET-Evidence interactive genomic report [Block et al., 2012]. This study deepened our understanding of the needs and practices of personal genomic users, highlighting that individuals are predominantly
Figure 5.2: Needs of non-experts seeking to learn from their personal genomic data information.

concerned with genetic variants that are well-established, pathogenic, and have high clinical importance.

While these insights are important for the development of interactive tools and reports, important questions about user engagement with personal genomics remain open.

5.1.2 Open questions for future research

In this section, we highlight two open questions for future HCI research on understanding users:

1. *Perceiving uncertainty and discrepancies:* Although personal genomic data are largely stable during a person’s lifetime, their interpretation and implications might change over time as new medical research exposes relationships between genes and health. In order to accurately communicate the inherent uncertainty of personal genomic interpretations, HCI research should investigate
5.1. Understanding users

how users of personal genomics perceive uncertainty and discrepancies between their personal genomic information, their experiences, and their family history. Such investigations could draw upon research the rich body of literature examining how lay individuals understand uncertainty in other domains (e.g. weather forecasting), which we discuss in Section 4.

2. Motivation for curating and sharing information: While personal genomic information is personal, it is also shared among families and community members. Curating and sharing findings from a personal genomic report could motivate families to seek the advice of healthcare providers, promote scientific understanding of relationships between genes and traits, enable biomedical research into rare conditions, and bring together communities of shared origins or interests. Additional research is required to understand how people curate personal genomic and related information, what factors influence people to share personal genomic information, what information they share with others, and with whom they share such information. Such research could be informed by the increasing amount of literature on family informatics [Colineau and Paris, 2011, Grimes et al., 2009, Pina et al., 2017] and on engaging patients and their family caregivers in perusal of patient-provided data and clinical data, e.g. [Grimes et al., 2009, Colineau and Paris, 2011, Chung et al., 2016, Woollen et al., 2016, Pina et al., 2017]

Qualitative HCI research methods including longitudinal semi-structured studies [Blandford et al., 2016] have an essential role in addressing these questions. However, when choosing a research method, careful attention should be directed toward considering the ethical implications of the study. Due to the sensitive nature of genetic testing, researchers should consider a range of ethics and privacy issues ranging from asking participants to share private information, to gathering sensitive information from social media and discussion groups, to presenting users with new interpretations of their personal genomic information that could drastically impact their understanding of their health risks, identities, and of their families.
5.2 Informing users

The decreasing costs of obtaining personal biological data, coupled with the proliferation of websites and digital devices for self-tracking and testing, have resulted in a reduced barrier to entry for participation in online biomedical research in general, and in genetic testing in particular, and have highlighted the importance of informed online consent processes. Taken together, these factors require us to re-evaluate the effectiveness and potential of digital, interactive consent in this new context of enrolling in biomedical research.

From an HCI perspective, interactive consent poses several challenges and opportunities to informing users: whereas individuals participating in biomedical research in general or in genetic testing in particular were formerly able to engage with a professional in a face-to-face dialogue, potential online research or DTCGT participants have fewer opportunities to ask questions and express their concerns in real time [Balestra et al., 2015]. Furthermore, presentation techniques and design interventions may influence an individual’s decision to participate [Friedman et al., 2000, Das et al., 2015], raising concerns about the voluntariness of participation. In response to such concerns, federal agencies are drafting guidelines for electronic consent [FDA, 2015]. At the same time, interactivity offers unique advantages to the consent-seeking and deliberation process: through interactive consent forms, consent seekers may provide additional on-demand information based on participants’ interests; through careful use of feedback and user analytics, consent seekers may also be able to gain insights into the parts of the consent forms that participants find more useful, more challenging, or requiring additional clarification. Yet another way in which web-based interactive consent forms can help the consent-seeking and deliberation process includes the use of social features, such as ratings, recommendations, and annotations. Such features could enable individuals deliberating on their consent decision to share information, evaluate different perspectives, and ultimately explore the risks and benefits of the research beyond the scope of one-on-one dialogue with a research staff member.
In addition to facilitating an informed consent process, HCI has an important role in enhancing non-expert comprehension of personal genomic reports, and in particular to help individuals make sense of the uncertainty of personal genomic data and its implications.

5.2.1 Current research on informing users

5.2.1.1 Improving online consent processes

The decision to consent to participate in medical research is mediated by two main factors: participants’ comprehension of the details of the study, and their trust in the research organization [Kneipp et al., 2009]. Recent studies on consent form design focus predominantly on the impact of content structure, graphical enhancements, and multimedia on comprehension [Dresden and Levitt, 2001, Dunn et al., 2002, Murphy et al., 2007, Stiles et al., 2001].

To understand how social features can enhance online consent forms, we studied the use of social annotations in personal genomic research [Balestra et al., 2016a,b]. First, we explored the impact of social annotation, embedded in online consent forms, on individuals’ informed consent beliefs and decisions. Participants were presented with an online consent form for a personal genomics study, and were randomly assigned to either a social annotation condition that exposed them to previous users’ comments on-screen (Figure 5.3), or to a traditional consent form without annotation. We compared participants’ perceptions about their consent decision, their trust in the organization seeking the consent, and their consent decision across conditions. We found that while consent rates did not differ across conditions, on average individuals exposed to social annotation felt that their decision was more informed, and furthermore, that the effect of the exposure to social annotation was stronger among users characterized by relatively lower levels of prior privacy-preserving behaviors.

In a second study [Balestra et al., 2016b], we focused on the influence of annotations’ valence on participants’ perceptions and behaviors surrounding online consent for biomedical research: participants were presented with an online consent form for a personal genomics study
2. How can I participate?

Participation in this study involves (1) providing your trait data and genetic data to the HCPGP private online database, and (2) consenting to the use of this data for research purposes. Your data will be used indefinitely and may be shared with authorized researchers.

Trait Data: Trait data will be collected by a phone interview, which will take about 30 minutes. Upon completion of the interview, your data will be saved to the HCPGP private online database. The trait data that is collected may include, but is not limited to: date of birth, medications, vaccines, diseases, personal and familial medical history, race, ethnicity, vital signs, and lifestyle traits.

Genetic Data: You will be sent materials for an at-home saliva collection. This kit is self-administered and typically requires you to provide 2-4 milliliters of your saliva. You will then send the saliva sample back to the laboratory in the prepaid package that is provided for you. Your genome will then be sequenced and analyzed in the lab. Your genomic data will be saved to the HCPGP private online database and a copy of the results will be sent to you.

3. Will I be compensated?

Participation in this study does not entitle you to any financial compensation. In the event that your genetic data contributes to a discovery, neither you nor your family will receive any financial benefit. However, by participating in this study, you will receive a copy of your genome data for free. This data may not be used as a clinical diagnostic, but may otherwise be used as you wish (e.g. for personal research). Purchasing your genome data through a commercial company currently costs around $2,000.

4. How will my data be kept private?

We have taken many measures to make sure that your data is kept confidential and private within the HCPGP private online database. Furthermore, researchers who conduct statistical analyses with your full genetic data will not have access to your name, address, or user ID. On the other hand, researchers who may interview you will have access to your name and contact information; however, they will only have limited access to a small amount of your genetic information. Only non-identifying information will be published in scientific journals.

<table>
<thead>
<tr>
<th>PGHCI: Consent Form Task</th>
<th>Section 6/8</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. How can I participate?</td>
<td></td>
</tr>
<tr>
<td>Participation in this study involves (1) providing your trait data and genetic data to the HCPGP private online database, and (2) consenting to the use of this data for research purposes. Your data will be used indefinitely and may be shared with authorized researchers. Trait Data: Trait data will be collected by a phone interview, which will take about 30 minutes. Upon completion of the interview, your data will be saved to the HCPGP private online database. The trait data that is collected may include, but is not limited to: date of birth, medications, vaccines, diseases, personal and familial medical history, race, ethnicity, vital signs, and lifestyle traits. Genetic Data: You will be sent materials for an at-home saliva collection. This kit is self-administered and typically requires you to provide 2-4 milliliters of your saliva. You will then send the saliva sample back to the laboratory in the prepaid package that is provided for you. Your genome will then be sequenced and analyzed in the lab. Your genomic data will be saved to the HCPGP private online database and a copy of the results will be sent to you.</td>
<td></td>
</tr>
<tr>
<td>3. Will I be compensated?</td>
<td></td>
</tr>
<tr>
<td>Participation in this study does not entitle you to any financial compensation. In the event that your genetic data contributes to a discovery, neither you nor your family will receive any financial benefit. However, by participating in this study, you will receive a copy of your genome data for free. This data may not be used as a clinical diagnostic, but may otherwise be used as you wish (e.g. for personal research). Purchasing your genome data through a commercial company currently costs around $2,000.</td>
<td></td>
</tr>
<tr>
<td>4. How will my data be kept private?</td>
<td></td>
</tr>
<tr>
<td>We have taken many measures to make sure that your data is kept confidential and private within the HCPGP private online database. Furthermore, researchers who conduct statistical analyses with your full genetic data will not have access to your name, address, or user ID. On the other hand, researchers who may interview you will have access to your name and contact information; however, they will only have limited access to a small amount of your genetic information. Only non-identifying information will be published in scientific journals.</td>
<td></td>
</tr>
</tbody>
</table>

Figure 5.3: A consent form for personal genomics research with social annotation, from [Balestra et al., 2016a,b]. Users can read comments on the right, and highlight text to leave their own comments.
that contained social annotations embedded in its margins. Individuals were randomly assigned to view the consent form with positive-, negative-, or mixed-valence comments alongside the text of the consent form. We compared participants’ understanding of the material and perceptions of informedness, their trust in the organization seeking the consent, and their consent across conditions. We found that consent forms containing positive-valence annotations are likely to lead participants to feel less informed and simultaneously more trusting of the organization seeking consent. In certain cases where participants spent little time considering the content of the consent form, participants exposed to positive-valence annotations were even more likely to consent to the study.

5.2.1.2 Transforming personal genomic reports to a long-term information partnership

Traditionally, informed consent is a one-time event in which a person agrees to participating in research and is informed of what is known to the science at that point in time. However, as medical research, and information about the relationships between genetic and health information develop, digital informed consent offer opportunities for long-term information partnerships between scientists and users. In such partnerships, the person consenting can be continuously informed of new knowledge about risks and benefits emerging from research, and the ensuing new interpretations of their genetic data. Furthermore, by combining the nature of genetic information as data-static but interpretation-dynamic with design that incorporates social features and curation, genetic data can be curated by the users or relevant others (including healthcare professionals, family members, or others with exposure to the user’s genetic data), such that emerging new research information is shared with the user based on their genetic profile. Such approach turns a one-time consent event to an ongoing informing mechanism which the user can enhance individually and socially. It also, however, represents potential risks of people consenting to one thing (based on existing medical knowledge at the time of consent) and being potentially exposed to information about other
things (based on advances in research). This may, in some cases, be more stressful or mentally taxing than these people had anticipated at the time of consent. Mechanisms can be designed for such cases, for example, by making the consent time-specific or with placing the control of information sharing extent with the user.

5.2.1.3 Increasing comprehension of personal genomic reports

Existing research has focused on participants’ comprehension of anonymous sample personal genetic reports. Lachance et al. [2010] examined the informational content, literacy demands, and usability of DTCGT service websites. They found that websites vary widely, and most users would struggle to use these resources effectively. The authors suggested that future tools focus on distilling and prioritizing important information while considering readability and usability elements. Other studies have looked more specifically at users’ comprehension of genomic reports. Ostergren et al. [2015] assessed participants’ comprehension of anonymized genomic reports and found that comprehension varied widely according to demographic characteristics, numeracy and genetic knowledge, and types and format of the genetic information presented. They suggested that the presentation of genomic data be tailored to the test type and to consumer characteristics. To investigate the effect of different visualizations on consumers’ understanding of personal genomic data, we conducted a comparative study, which indicated an advantage to non-zoomable visualizations, with best results (in terms of both objective comprehension and subjective preference) from using bubble graphs [Shaer et al., 2015].

In contrast to the studies, which presented users with anonymized genetic data, Kuznetsov et al. [2015] presented users with their own 23andMe data to understand how they make sense of and contextualize their results, critique and evaluate the underlying research, and consider the broader implications of genetic testing. They framed consumers as members of biocitizen publics in which there is an emphasis on individuals’ engagement with the community and higher-order learning processes [Airasian et al., 2001], rather than merely perceiving
5.2. Informing users

results and individually gathering information. The authors recommend the development of platforms for aggregating hybrid knowledge for creative reflection on professional science, and for supporting collaborations across communities.

5.2.1.4 Communicating uncertainty

The personal genomics context offers a form of uncertainty not addressed by existing taxonomies and applications. In the genomics context, unlike most personal informatics contexts, the full data set is known and is mostly stable — the source of uncertainty is the interpretation of the data, which depends on new scientific findings. Furthermore, personal genomics requires the communication of multidimensional uncertainty — uncertainty that emerges from the accumulation of several levels of uncertainty that the user encounters. Consider for example cases where known relationships between genetic characteristics and medical conditions convey a probabilistic message (e.g. that the carrier of a certain genetic variant has a 10% likelihood of developing a certain medical condition). On top of that uncertainty, consider cases where the data supporting this relationship between the variant and the medical condition is not well-established empirically, or that it is based on studies that have not been replicated. Such accumulation of even two sources of uncertainty is highly complicated for most non-expert users, and more research is needed in order to understand how to convey such information to non-experts in understandable ways. Karczewski et al. [2012] stress the importance of teaching the methods of genetic risk calculations.

5.2.2 Open issues for future research

The following are some of key issues to be addressed by future HCI research on informing users:

1. Enhancing the online consent process with social features: while recent research indicates that adding social annotation to online consent forms could potentially inform participants and improve their deliberation processes, many research questions remain
Emerging Framework for HCI for Personal Genomics

open. For example, what are the most effective ways to solicit useful content for social annotation? How, whether, and to what extent should the content contributed by non-expert users through social annotation tools be curated and edited before it is presented to readers of informed consent forms? If such curation takes place, who should be in charge of it? To what extent should the social intervention be based on explicit user choices — for example, should the exposure to social annotation be based on opt-in versus opt-out design defaults? What other social interventions can be considered for an interactive informed consent form? And, finally, what are the ethical concerns associated with interventions in consent forms, and what are the responsibilities of the consent seekers in this respect?

2. Personalized presentation and user choice: existing research suggests that the presentation of genomic information be tailored to the test type and to the characteristics of the user. However, more research is required to understand what elements should be interactive and/or customized and in what ways. What are the best practices for design interventions that are tailored, transparent, and valuable to the user? How much autonomy should the user receive to make sure they are well-informed, and to what extent should design interventions be based on explicit user choices?

3. Communication of multidimensional uncertainty: delivering personal genomic information to users requires the communication of multidimensional uncertainty — that is, uncertainty that emerges from the accumulation of several dimensions of uncertainty the user encounters. Communicating such accumulating uncertainty is not currently well addressed by existing taxonomies and tools, and poses a challenge to researchers and practitioners. Open questions for researchers and practitioners include: How to best construct effective representations of multidimensional uncertainty? How should different levels of visual and statistical literacy be served through interactive tools to facilitate multidimensional uncertainty communication? And finally, how to evaluate users'
5.3 Empowering users

The applicability of personal genomic information to individuals, and its evolving understanding based on new scientific discoveries, evoke compelling HCI questions when considering digital tools that mediate the interaction between the individual and their data: What are the functional requirements for supporting meaningful engagement with personal genomic information? How can we design tools which allow users to explore and make sense of their personal genomic information? How can we design tools that support long-term engagement and personal research? How can we empower users to contextualize and act upon their genomic information?

Interaction with personal genomic data often begins by reviewing a personalized genetic report [Shaer et al., 2015]. Thus, the design of interactive reports for non-expert individuals that support sensemaking and exploration plays a vital role in empowering people to learn from and engage with their personal genomic information. Self-exploration tools should also enable non-experts to contextualize and compare their personal genomic information with other individuals (e.g. family members), ancestry information, and family medical history [Kuznetsov et al., 2015] as well as to share information with a doctor, friends, family, or the public. Finally, since genetic research evolves with the development of novel technologies, processes, and new scientific findings, tools for non-experts should support long-term engagement, allowing people to re-interpret their information in light of new scientific findings as well as personal developments.

5.3.1 Current research on empowering users

Our studies with personal genomic users indicate that non-expert individuals mostly use the tools offered by their genetic data provider (e.g.
23andMe, PGP, AncestryDNA, 2016, fTree) [Shaer et al., 2014, Shaer and Nov, 2014]. However, tools offered by DTCGT companies provide interpretations that reflect the preferences and limitations of the genetic testing company and are mostly not customizable by the individual users. Typically, the results can only be generated and curated by the DTCGT company. Also, since DTCGT tools may use proprietary algorithms, their genome analysis is not always transparent to the user and the user may not understand how the analysis was done or be able to replicate the results with other tools [Karczewski et al., 2012].

Many of our study participants [Shaer et al., 2014, Shaer and Nov, 2014] have found the existing tools, both those offered by DTCGT providers and other online tools, to be too complicated and overwhelming in terms of the amount of information they present and their use of scientific jargon.

To address these challenges, we presented a design case study of a novel interactive tool, named GenomiX, which was developed using a user-centered design process [Shaer et al., 2016]. It is important to note that GenomiX does not provide new genome interpretations but rather draws upon the interpretation provided by the Harvard PGP’s GET-Evidence report. The requirements and design goals of GenomiX draw upon findings from our previous research exploring users’ motives, needs, and interaction patterns with genomic data [Shaer et al., 2015].

Drawing upon these findings, we defined the following goals for an interactive tool for exploring personal genomic information: (G1) Presenting a visual summary of personal genomic information that highlights which variants are potentially concerning and require further investigation; (G2) Communicating the level of certainty of the scientific evidence associating a particular gene variant to health conditions. Since the certainty of the evidence can change over time, the report needs to provide up-to-date evidence. (G3) Relating variants to medical conditions while conveying complex relations, which associate multiple variants with a particular condition or the same variants with multiple conditions. (G4) Allowing users to curate information about variants, giving them a basis from which to conduct further research.

GenomiX is implemented as a web tool, presenting the user with a visualization that provides an overview of their genetic variant data
5.3. **Empowering users**

(Figure 5.4). Gene variants are represented as bubbles that are plotted between two axes: clinical importance (X axis), and certainty of evidence (Y axis); the size, color, and placement of these bubbles communicate specific information about each variant. Individuals can sort the data on the plot by either risk or rarity of the variant. Alternatively, users can view a report organized by categories where variants are sorted according to the anatomical system they might impact (see Figure 5.5). Users can save information about particular gene variants to a Notebook tab. GenomiX also offers contextual help regarding terminology as well as a glossary.

In addition to an interactive visual gene variant report, GenomiX offers Curator, a tool designed to help users curate personal genomic information, make new connections, and engage with their personal genomic information over time. Curator consists of two parts: a downloadable Google Chrome extension, which allows users to save web pages, pdf files, videos, and images; and a Notebook, which displays gene variants and web pages that a user has saved (Figure 5.6).
Figure 5.5: GenomiX: Gene Variant Report displaying participant’s results sorted by category.

Figure 5.6: The Notebook tool, displaying gene variants and web pages that a user has saved.
5.3. Empowering users

To evaluate the usability and utility of GenomiX, we conducted the first study of a new genome interpretation tool to date, in which users viewed their own personal genomic data [Shaer et al., 2016]. Our findings indicate that GenomiX offered its users a number of benefits afforded by the tool’s design features: visually reducing complexity improves users’ ability to prioritize gene variants, communicating uncertainty helped users when interpreting genomic data and choosing which variants to focus on, and color coding helped users to identify information they overlooked in prior tool such as distinguishing protective or carrier variants.

While the design and evaluation of GenomiX offer insights into the development of future interactive personal genomics exploration tools, there are a number of key issues that should be considered in future research about tools for empowering non-experts’ self-exploration of personal genomics. Future research should also draw upon lessons from a rich body of research on using genetic data to empower patients in the context of clinical care [e.g., Gilbar, 2007, Rosas-Blum et al., 2007, Berg et al., 2017]. Such lessons could be helpful in the design of novel tools for personal genomics exploration.

5.3.2 Open issues for future research

Here, we highlight three key issues for future HCI research on empowering users:

1. **Comparing and relating genomes**: while existing tools present users with their own ancestry and allow relatives to view which segments of their DNA are shared (or not shared) between two individuals, additional research is needed to enable users to compare and relate genomes in order to understand trait- and health-related information. Scientific methods to understand risk in the context of genome-sharing among family members are complex and are still evolving. Contextualizing genetic testing results in respect to other family members or friends could play an important role in understanding and acting upon personal genomic information. However, many questions remain open. What criteria for comparison are meaningful and informative for
non-experts? How to visualize multiple genome comparison for non-experts in an effective manner? And how to facilitate sharing of information for comparison across individuals?

2. Facilitating sharing: from a societal perspective, information sharing is an important aspect of users’ engagement with personal genomic information. However, sharing such information is rarely facilitated by existing tools, and is mostly limited to exploring ancestry and to discovering new biological relatives. Information sharing can be supported in a number of forms:

(1) Sharing personal genomic information: users can share their genomic information with other users (e.g. family members), with their healthcare provider, with research projects such as Harvard’s PGP, or with commercial efforts such as 23andMe. In each one of these cases, users may choose to share some parts of their information and withhold others;

(2) Sharing meta-information with social circles: this category includes all information that is not the actual personal genomic data, but rather related to it. The recipients of the information are the user’s social circles, online and offline. Examples of such meta-information sharing include: the fact the user shared their information with a research project, the user’s thoughts about genomic information and the role they play and can play in modern medicine, and things the user learned as a result of engaging with their personal genomic information. The value of this type of information-sharing stems from its social impact: sharing such meta-information helps to increase awareness about the opportunities and challenges associated with sharing personal genomic information;

(3) Sharing interpretations, insights, and other relevant information based on self and others’ personal genomic information. Examples of such information sharing include new scientific research findings related to personal genomic data
5.3. **Empowering users**

(of self or others) along with explanations of how the new research findings may be relevant to the genomic information, and what other relevant information might be needed as a next step in exploring it, or pointers for others who shared their information about relevant online resources or communities (e.g. online communities of people with certain medical conditions).

In all of the cases above, in addition to understanding users’ needs and concerns about sharing genomic information, it is important to investigate which design and implementation features allow for sharing while also supporting transparency regarding access, storage, and usage, and ensuring users control the level of privacy they prefer.

3. **Evaluation methods** — Personal genomic data are personal, and therefore more studies are needed in which participants are presented with their own data. Prior studies on user-facing genomics tools mostly use fictional or anonymized data; that is, genomic test results that do not belong to the participant. Thus, these studies fail to incorporate the impact and meaning of the data to the user whose data is reported. Also, existing studies tend to use novice participants who are unfamiliar with their genomic data to evaluate visualizations, thereby being unable to look at participants’ evolving understanding of their genome, or how well a proposed tool or platform provides new insights. Future studies should further investigate how new tools allow users to explore and learn from their own data. In addition, tools for self-exploration of personal genomics have the potential to help users make sense of their genomic data over time as the research that links this data to health outcomes evolves, and as users’ personal circumstances change. Longitudinal studies are needed to examine participants’ information needs and interactions over time and to understand how the use of personal genomic tools changes and how to support users over time.
Making interaction with personal genomic information more accessible for non-experts, has broader implications for HCI researchers, practitioners, policymakers, and society.

6.1 For HCI researchers

Personal genomics presents a unique challenge to HCI scholars and practitioners: while many contributions to HCI and personal informatics focus on novel ways to represent constantly-changing data, personal genomics represents the opposite case: data is sampled only once and is largely static over the user’s lifetime, but the interpretation of the data, as well as its importance, can change dramatically over time, with new medical research revealing hitherto unknown relations between genetic characteristics on one hand and physical attributes or medical conditions on the other. This combination of static information and dynamic interpretation calls for new HCI approaches and tools that allow capturing dynamically and constantly changing new knowledge about a stable data set. Such new tools may include dynamic curation of information related to genetic data, or adaptive decision support tools and
visualization, which change based on incoming new medical research. A related issue concerns the development of tools to facilitate sharing of this unique information–interpretation combination: future tools will need to facilitate sharing with relevant others (e.g. family members, health providers, or scientists) not only personal genomic information, but also its changing interpretations, which may require the attention — and in some cases action — of others. Finally, advances in HCI research may contribute to better communication of multidimensional uncertainty by exploring the potential use of interactive, customized, and adaptive design.

6.2 For practitioners

HCI research can also contribute to the work of practitioners in areas related to personal genomics by exploring what information users value and what information they are likely to be confused by. By studying information behavior in a personal genomics context, we can improve the ways in which genetic findings are communicated to users in clinical and non-clinical settings. Products and tools based on HCI research may also underpin the development of an ecosystem of commercial and non-commercial services based on added layers of information, and on connecting people with relevant information, with relevant service providers and with each other.

6.3 For society and policymakers

Better understanding and more effective engagement of users with their personal genomic information can help increase genetic and health literacy among non-experts. Moreover, rich and effective engagement may also lead to the further growth of burgeoning genomics-based citizen science, in which members of the public contribute to professional research projects as they collectively interpret and critique relevant information [Kuznetsov et al., 2015]. The accumulation of personal genomic data and analysis contributed by members of the public can support the work of professional scientists in diverse areas such as genetics, public health, and others.
Broader Implications

HCI work on personal genomics can also inform public discourse about the relationship between people and their personal information, and in addition, between people and entities who can benefit from access to this personal information such as researchers, healthcare providers, commercial companies, and public health organizations. As the scope of personal genomics grows and its effects on the public become clearer, HCI work can inform regulators, policymakers, and standard-setting institutions as they devise policies and regulations on how personal genomics should be presented to the individuals (1) statically, (2) interactively, and (3) dynamically. Recent events in which the FDA barred and then allowed personal genomics company 23andMe to offer personal genomic health-related reports to its users [Pollack, 2015] exemplify some of the sensitivities and complexities involved in how government can regulate the exposure of individuals to their personal genomic data, and how interpretation of such data can or should be provided to non-experts.

Finally, a societal aspect of the growing availability of DTCGT services is that their customer base tends to gravitate toward white and well-educated users [Roberts and Ostergren, 2013]. It is therefore our role as researchers to increase awareness and understanding of genetic information and its implications to populations that are underrepresented in this user base. It should be also noted, that at a societal level, enabling wide-spread understanding of the commonalities — and in particular, genealogical similarities — among people from different ethnic backgrounds may contribute toward reducing racial categorization and bias.
Acknowledgements

We would like to thank Christina Pollalis and Clarissa Verish for their contribution. This work was partially funded by Grants IIS-1017693 and IIS-1422706 from the National Science Foundation (NSF), Division of Information and Intelligent Systems (IIS).
References


References


V. Hughes. It’s time to stop obsessing about the dangers of genetic information. Slate, Date accessed 29 July 2016, URL: http://www.slate.com/articles/health_and_science/medical_examiner/2013/01/ethics_of_genetic_information_whole_genome_sequencing_is_here_and_we_need.html, 2013.


References


References


O. Shaer, O. Nov, J. Okerlund, M. Balestra, E. Stowell, L. Westendorf, C. Pol-
lalis, J. Davis, L. Westort, and M. Ball. Genomix: A novel interaction tool

M. Skeels, B. Lee, G. Smith, and G. Robertson. Revealing uncertainty for
information visualization. In Proceedings of Advanced Visual Interfaces,

P. G. Stiles, N. G. Poythress, A. Hall, D. Falkenbach, and R. Williams.
Improving understanding of research consent disclosures among persons

M. Swan. Emerging patient-driven health care models: An examination of
health social networks, consumer personalized medicine and quantified self-
tracking. International Journal of Environmental Research and Public

B. N. Taylor and C. E. Kuyatt. Guidelines for evaluating and expressing the

J. Thomson, E. Hetzler, A. MacEachren, M. Gahegan, and M. Pavel. Typology
for visualizing uncertainty. In Proceedings of the IS&T/SPIE Symposium on
Electronic Imaging, Conference on Visualization and Data Analysis, pages

E. Troshynski, C. Lee, and P. Dourish. Accountabilities of presence: Refram-
ing location-based systems. In Proceedings of the SIGCHI Conference on

M. Turrini and B. Prainsack. Beyond clinical utility: The multiple values of

A. Tversky and D. Kahneman. Judgment under uncertainty: Heuristics and

E. Vayena, E. Gourna, J. Streuli, E. Hafen, and B. Prainsack. Experiences of
early users of direct-to-consumer genomics in switzerland: An exploratory

J. Woollen, J. Prey, L. Wilcox, A. Sackeim, S. Restaino, S. T. Raza, S. Bakken,
S. Feiner, G. Hripcsak, and D. Vawdrey. Patient experiences using an
inpatient personal health record. Applied Clinical Informatics, 7(2):446–
460, 2016.

A. Wu, J. B. Yim, E. Caspary, A. Mazalek, S. Chandrasekharan, and N. J.
Nersessian. Kinesthetic pathways: A tabletop visualization to support dis-
covery in systems biology. In Proceedings of the 8th ACM Conference on